For more than 35 years, we've been enabling genomics laboratories with an oligonucleotide manufacturing process unlike anyone else in the industry, with the most advanced synthesis, modification, purification, and quality control capabilities available.
Through our founder's dedication to innovation, the highest standards of quality, and deep genomics expertise, IDT has evolved from a leading oligo manufacturer to a genomics solutions provider supporting key areas such as next generation sequencing, CRISPR, synthetic biology, and
PCR, equipping researchers with the right tools when they needed them. With these core efforts, IDT teams have been behind the scenes helping to drive science forward with increased quality, volume, efficiencies, and unmatched customer service.
Today, technology is evolving faster than ever before. Scientists leading the transition from basic to translational research face new challenges with securing the custom solutions necessary to advance their research out of the lab and into the clinic.
These emerging barriers have collectively slowed down critical discoveries with potentially profound impacts on human and ecological health.
To help overcome these obstacles and push the boundaries of technology, we've expanded production facilities and capabilities to include GMP* and cGMP manufacturing grades. These additions provide customers with a genomics solutions partner capable of
supporting the entire research journey. Combined with a renewed collaborative agility, members of our organization and strategic partners are positioned to contribute to the greatest genomic breakthroughs of our time—guiding more effective
vaccines, addressing world hunger and climate change, and driving new diagnostics and therapeutics for complex diseases.
As we look to the future, our mission—accelerating the pace of genomics—honors our legacy and represents our commitment to the pursuit of new ideas that will help us realize our shared vision of enabling researchers to rapidly move from the
lab to life-changing advances.